| Fan, Yun |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
HS-20117 301, NCT06417008: A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2/3 | 1080 | NA | HS-20117, PM1080, Aumolertinib, Almonertinib Mesilate Tablets, HS-10296, Almonertinib | Hansoh BioMedical R&D Company | Non-Squamous Non-Small Cell Lung Cancer | 06/26 | 06/30 | | |
NCT05844150: A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC |
|
|
| Recruiting | 2/3 | 445 | RoW | PM8002, Platinum, Atezolizumab, Etoposide | Biotheus Inc. | SCLC | 06/25 | 12/25 | | |
ACHIEVE, NCT04808752: Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases |
|
|
| Active, not recruiting | 2 | 63 | RoW | Almonertinib, Investigational Product | Zhejiang Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer | 06/24 | 07/24 | | |
NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors |
|
|
| Recruiting | 2 | 121 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma | 11/25 | 11/25 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT05728619: HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer |
|
|
| Recruiting | 1b/2 | 64 | RoW | HTMC0435, Temozolomide | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Recurrent Extensive Stage Small Cell Lung Carcinoma | 08/24 | 10/24 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Recruiting | 1/2 | 233 | RoW | AK112, AK104, Carboplatin, paclitaxel, pemetrexed, Docetaxel | Akeso | Advanced Non-small-cell Lung Cancer | 04/25 | 01/27 | | |
NCT05951608: A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 216 | NA | AK127 in combination with AK112 | Akeso | Advanced Solid Tumors | 07/25 | 07/26 | | |
NCT05393063: A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 36 | NA | AK127, Subjects will receive AK127 by intravenous administration | Akeso | Advanced Solid Tumors | 06/23 | 06/24 | | |
NCT05315180: A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 80 | RoW | BPI-421286 | Betta Pharmaceuticals Co., Ltd. | Malignant Neoplasms, Metastatic Cancer | 07/23 | 07/23 | | |
NCT06641609: A Phase I Study of CFT8919 in Patients With Advanced NSCLC |
|
|
| Not yet recruiting | 1 | 166 | RoW | Dose-Escalation (Phase Ia) CFT8919 capsule, CFT8919, Dose-Expansion (Phase Ib) CFT8919 capsule, Cohort-Expansion (Phase Ic) CFT8919 capsule | Betta Pharmaceuticals Co., Ltd. | Non-Small Cell Lung Cancer With EGFR Mutation | 12/25 | 04/26 | | |
